Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:08:44.703Z.
Consensus retrieved: 2026-10-06T14:28:17.455Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:08:44.703Z.
Quote observation: 2026-10-06T18:05:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7a446221ee70341de49d615c46e15f9be625c30a72cedc9ff9e6473dbc59ae23
Forward PE Ratio (N/A) = Dated Quote Price ($2.94) / Consensus Forward EPS ($-0.87)
FORWARD PE RATIO
N/A
NRx Pharmaceuticals, Inc.
Market Cap
$127.29M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| NRx Pharmaceuticals, Inc. (NRXP) | $127.29M | N/A |
| Entera Bio Ltd. (ENTX)vs › | $126.92M | N/A |
| Pyxis Oncology, Inc. (PYXS)vs › | $128.93M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $124.90M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $123.23M | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $132.64M | N/A |
| Seer, Inc. (SEER)vs › | $121.78M | N/A |
| Cibus, Inc. (CBUS)vs › | $121.37M | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $133.33M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.94, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.87 | $-1.42 – $-0.57 | 2 | n/m |
| 2027-12-31 | $-0.41 | $-0.67 – $-0.27 | 2 | n/m |
| 2028-12-31 | $0.15 | $0.10 – $0.24 | 1 | 19.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
